These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11886463)

  • 21. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre.
    Smejkal P; Brabec P; Matyskova M; Bulikova A; Slechtova M; Kissova J; Chlupova G; Muzik J; Penka M
    Haemophilia; 2009 May; 15(3):743-51. PubMed ID: 19432925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.
    Berntorp E
    Baillieres Clin Haematol; 1996 Jun; 9(2):259-71. PubMed ID: 8800504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Haemophilia care in Europe: the ESCHQoL study.
    Schramm W; Gringeri A; Ljung R; Berger K; Crispin A; Bullinger M; Giangrande PL; Von Mackensen S; Mantovani LG; Nemes L; Serban M;
    Haemophilia; 2012 Sep; 18(5):729-37. PubMed ID: 22639833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Healthcare resource utilization among haemophilia A patients in the United States.
    Valentino LA; Pipe SW; Tarantino MD; Ye X; Xiong Y; Luo MP
    Haemophilia; 2012 May; 18(3):332-8. PubMed ID: 22044662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
    Khawaji M; Astermark J; Berntorp E
    Eur J Haematol; 2012 Apr; 88(4):329-35. PubMed ID: 22221195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Forum on: the role of recombinant factor VIII in children with severe haemophilia A.
    Franchini M; Coppola A; Molinari AC; Santoro C; Schinco P; Speciale V; Tagliaferri A
    Haemophilia; 2009 Mar; 15(2):578-86. PubMed ID: 19187188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying and overcoming barriers to prophylaxis in the management of haemophilia.
    Petrini P
    Haemophilia; 2007 Sep; 13 Suppl 2():16-22. PubMed ID: 17685919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).
    Meunier S; d'oiron R; Chambost H; Dolimier E; Guillet B;
    Thromb Res; 2017 Mar; 151():17-22. PubMed ID: 28088606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic issues in European self-sufficiency.
    Szucs TD
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S51-5. PubMed ID: 7795140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose tertiary prophylactic therapy reduces total number of bleeds and improves the ability to perform activities of daily living in adults with severe haemophilia A: a single-centre experience from Beijing.
    Hua B; Lian X; Li K; Lee A; Poon MC; Zhao Y
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):136-40. PubMed ID: 26258677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
    Feldman BM; Rivard GE; Babyn P; Wu JKM; Steele M; Poon MC; Card RT; Israels SJ; Laferriere N; Gill K; Chan AK; Carcao M; Klaassen RJ; Cloutier S; Price VE; Dover S; Blanchette VS
    Lancet Haematol; 2018 Jun; 5(6):e252-e260. PubMed ID: 29731369
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
    Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
    Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic evaluation: what are we looking for and how do we get there?
    Steen Carlsson K; Höjgård S; Lethagen S; Berntorp E; Lindgren B
    Haemophilia; 2004 Mar; 10 Suppl 1():44-9. PubMed ID: 14987248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis.
    Smith PS; Teutsch SM; Shaffer PA; Rolka H; Evatt B
    J Pediatr; 1996 Sep; 129(3):424-31. PubMed ID: 8804333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors.
    Mahlangu JN
    BioDrugs; 2018 Dec; 32(6):561-570. PubMed ID: 30430367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
    Berntorp E
    Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.